Influenza virus vaccines and uses thereof
Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Europäisches Patentamt - (2019) vom: 31. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MEIJBERG JAN WILLEM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2019-12-31, Last update posted on www.tib.eu: 2024-03-06, Last updated: 2024-03-15 |
|---|
| Patentnummer: |
US10517941 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000025518 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000025518 | ||
| 003 | DE-627 | ||
| 005 | 20240315100422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000025518 | ||
| 035 | |a (EPA)US10517941 | ||
| 035 | |a (EPA)48485075 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MEIJBERG JAN WILLEM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influenza virus vaccines and uses thereof |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2019-12-31, Last update posted on www.tib.eu: 2024-03-06, Last updated: 2024-03-15 | ||
| 520 | |a Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a IMPAGLIAZZO ANTONIETTA |4 aut | |
| 700 | 0 | |a RADOSEVIC KATARINA |4 aut | |
| 700 | 0 | |a WADIA JEHANGIR |4 aut | |
| 700 | 0 | |a WILLIAMSON ROBERT ANTHONY |4 aut | |
| 700 | 0 | |a WAGNER MICHELLE |4 aut | |
| 700 | 0 | |a DING ZHAOQING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2019) vom: 31. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/48485075/publication/US10517941A1?q=US10517941 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2019 |b 31 |c 12 | ||